vivitide, LLC

Based in Massachusetts, US, and founded in 2019, vivitite, LLC was formed by the merger of New England Peptide, Inc. and Peptides International, Inc. , which operates as a peptide and polyclonal antibody manufacturer. In March 2022, Carbosynth Limited, a portfolio company of KKR, acquired vivitite, LLC from Ampersand Capital Partners.

As of 2022, the company’s CEO is Martina Diekmann. The products manufactured by the vivitide, LLC include RGD peptides, TrypTides (tryptic peptides for proteomics research), stable isotope-labeled peptides and amino acids, various receptor agonists and antagonists (including PAR, GLP-1, NPY, bradykinin, ghrelin), hepcidins, venoms and toxins, cell-penetrating peptides, peptide macrocycles, enzyme inhibitors and substrates (including TAPI, FRET, MMP, protease), biomarkers, click chemistry products, mini-PEG™ solubilizing linkers, CLEAR-OX™ polymer-supported oxidants, and combinatorial peptide libraries. The services offered by the company include custom peptides, which include custom peptide synthesis, custom peptide arrays, tryptides-SIL (stable isotope-labeled) peptides, custom SIL peptides; custom antibodies, which include antibody production, custom polyclonal antibodies, custom monoclonal antibodies, TrypBodies™; antibodies for Immuno-MRM (iMRM)-SISCAPA®; proteomics tools, which include TrypBodies™; antibodies for Immuno-MRM (iMRM)-SISCAPA®, TrypTides-SIL peptides, custom SIL peptides; and custom services, which include analytical services, amino acid analysis. Following the March 2022 acquisition, the company plans to accelerate its growth and expand its product offerings and services.